BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023
– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant…
Telnyx Launches “LiveKit on Telnyx” for Deploying Voice AI Agents with Lower Cost and Ultra-Low Latency